Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00655122 |
The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects. The secondary objective was a pharmacoeconomic evaluation of hromboprophylaxis with dalteparin sodium in primary care medical subjects.
Condition | Intervention | Phase |
---|---|---|
Thromboembolism Deep Vein Thrombosis Dalteparin |
Drug: Dalteparin sodium Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Double-Blind, Placebo-Controlled, Pilot Study, In Medical Patients With Prophylaxis Of Venous Thromboembolism in Primary Care |
Enrollment: | 8 |
Study Start Date: | April 2003 |
Study Completion Date: | December 2003 |
Arms | Assigned Interventions |
---|---|
Dalteparin sodium: Active Comparator |
Drug: Dalteparin sodium
Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
|
Placebo: Placebo Comparator |
Drug: Placebo
Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
|
The study was prematurely terminated on December 9, 2003. The reason for the early termination was not related to a safety or efficacy issue. It was related to the difficulty in recruiting patients.
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Pfizer Investigational Site | |
Parla, Spain | |
Pfizer Investigational Site | |
Madrid, Spain | |
Pfizer Investigational Site | |
Leon, Spain, 24005 | |
Pfizer Investigational Site | |
Torremolinos, Spain, 29620 | |
Pfizer Investigational Site | |
Madrid, Spain, 28001 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | FGMAEI-0042-046, A6301036 |
Study First Received: | April 4, 2008 |
Last Updated: | September 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00655122 History of Changes |
Health Authority: | Spain: Spanish Agency of Medicines |
Anticoagulants Heparin, Low-Molecular-Weight Vascular Diseases Fibrinolytic Agents Cardiovascular Agents Venous Thromboembolism Thrombosis |
Thromboembolism Embolism and Thrombosis Fibrin Modulating Agents Embolism Dalteparin Venous Thrombosis |
Anticoagulants Molecular Mechanisms of Pharmacological Action Hematologic Agents Vascular Diseases Fibrinolytic Agents Cardiovascular Agents Venous Thromboembolism Thromboembolism |
Thrombosis Pharmacologic Actions Embolism and Thrombosis Fibrin Modulating Agents Dalteparin Therapeutic Uses Venous Thrombosis Cardiovascular Diseases |